We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo WHX Labs Dubai 2026 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

PCR-Based Molecular Platform to Enable Drastically Faster Bacterial Infection Diagnosis

By LabMedica International staff writers
Posted on 08 Jun 2023
Image: Molecular Culture® technique enables drastically faster and more accurate bacterial diagnostics (Photo courtesy of inbiome)
Image: Molecular Culture® technique enables drastically faster and more accurate bacterial diagnostics (Photo courtesy of inbiome)

A new novel PCR-based molecular platform provides a significant advancement in diagnosing bacterial infections by offering an alternative to traditional culture methods and outperforming newer methods such as sequencing on the time and cost front, while also matching the scope of other PCR tests.

Inbiome’s (Amsterdam, the Netherlands) Molecular Culture technique significantly speeds up and improves the precision of bacterial diagnostics compared to traditional culture. This revolutionary diagnostic technique has the capability to identify the vast majority of bacterial species through a single test. It is particularly tailored to deliver accurate results from invasively collected samples, such as cerebrospinal fluid, pus, and joint aspirates. Unlike culture or traditional PCR-based methods, Molecular Culture is not selective, which means medical professionals don't need to decide in advance which bacteria to search for. Since it is based on DNA detection, it can easily identify or detect bacteria that are unknown, uncultivable or have been treated with antibiotics.

Compared to conventional tests, Molecular Culture is more sensitive and precise. It accurately diagnoses almost double the number of positive samples, significantly reducing the prevalence of false negatives often associated with traditional testing. This leads directly to more informed treatment decisions, consequently improving patient outcomes. Moreover, the diagnostic process is quick, efficient, and simple. It delivers reliable and actionable results within four hours without the need for specialized equipment or bioinformatics pipelines. This means patients recover more quickly, complications are minimized, and the duration of hospital stays is substantially reduced. Currently, Molecular Culture is being utilized in several hospitals in the Netherlands, demonstrating exceptional results.

Related Links:
inbiome

Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Alcohol Testing Device
Dräger Alcotest 7000
Gold Member
Collection and Transport System
PurSafe Plus®

Channels

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more